ECSP13013117A - Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina. - Google Patents

Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina.

Info

Publication number
ECSP13013117A
ECSP13013117A ECSP13013117A ECSP13013117A EC SP13013117 A ECSP13013117 A EC SP13013117A EC SP13013117 A ECSP13013117 A EC SP13013117A EC SP13013117 A ECSP13013117 A EC SP13013117A
Authority
EC
Ecuador
Prior art keywords
methods
multiple sclerosis
reducing
content
myeline
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Katherine Dawson
Neill Gllmore O
Alfred Sandrock
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47217796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13013117(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of ECSP13013117A publication Critical patent/ECSP13013117A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ECSP13013117 2011-05-26 2013-12-26 Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina. ECSP13013117A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490572P 2011-05-26 2011-05-26
US201261625624P 2012-04-17 2012-04-17

Publications (1)

Publication Number Publication Date
ECSP13013117A true ECSP13013117A (es) 2014-06-30

Family

ID=47217796

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013117 ECSP13013117A (es) 2011-05-26 2013-12-26 Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina.

Country Status (19)

Country Link
US (1) US20140163100A1 (enExample)
EP (1) EP2713724A4 (enExample)
JP (1) JP2014515373A (enExample)
KR (1) KR20140036257A (enExample)
CN (1) CN103732062A (enExample)
AU (1) AU2012258558A1 (enExample)
BR (1) BR112013030169A2 (enExample)
CA (1) CA2836480A1 (enExample)
CL (1) CL2013003358A1 (enExample)
CO (1) CO6811862A2 (enExample)
EA (1) EA201391578A1 (enExample)
EC (1) ECSP13013117A (enExample)
IL (1) IL229448A0 (enExample)
MX (1) MX2013013781A (enExample)
PE (1) PE20141316A1 (enExample)
PH (1) PH12013502443A1 (enExample)
SG (1) SG195049A1 (enExample)
WO (1) WO2012162669A1 (enExample)
ZA (1) ZA201308681B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1663197T3 (da) 2003-09-09 2008-01-07 Fumapharm Ag Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma
SI1799196T1 (sl) 2004-10-08 2016-10-28 Forward Pharma A/S Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
MX2011001341A (es) 2008-08-19 2011-03-29 Xenoport Inc Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso.
PE20141639A1 (es) 2011-06-08 2014-11-08 Biogen Idec Inc Proceso para preparar fumarato de dimetilo de alta pureza y cristalino
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140057918A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
US9597292B2 (en) 2012-08-22 2017-03-21 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
AR094277A1 (es) 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
MX386935B (es) 2013-03-14 2025-03-04 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
CN103724198A (zh) * 2013-11-28 2014-04-16 镇江圣安医药有限公司 富马酸二甲酯的新型衍生物及其应用
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
CA2939990C (en) 2014-02-28 2018-07-10 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
CA2965449C (en) * 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
MA40985A (fr) * 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
MA41139B1 (fr) * 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
HUE057865T2 (hu) 2014-12-11 2022-06-28 Actelion Pharmaceuticals Ltd A poneszimodra, egy szelektív S1P1 receptor agonistára vonatkozó adagolási rend
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
HUE032251T2 (en) * 2007-02-08 2017-09-28 Biogen Ma Inc Neuroprotection in demyelinating diseases
EP2653873B8 (en) * 2007-02-08 2022-08-24 Biogen MA Inc. Compositions and uses for treating Multiple Sclerosis
MX2011001341A (es) * 2008-08-19 2011-03-29 Xenoport Inc Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso.
EP3318249A1 (en) * 2009-04-29 2018-05-09 Biogen MA Inc. Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
PE20141316A1 (es) 2014-10-01
KR20140036257A (ko) 2014-03-25
WO2012162669A1 (en) 2012-11-29
MX2013013781A (es) 2014-01-08
CN103732062A (zh) 2014-04-16
JP2014515373A (ja) 2014-06-30
EP2713724A4 (en) 2015-03-11
IL229448A0 (en) 2014-01-30
ZA201308681B (en) 2017-11-29
EP2713724A1 (en) 2014-04-09
AU2012258558A1 (en) 2013-05-02
PH12013502443A1 (en) 2019-03-22
BR112013030169A2 (pt) 2016-08-09
CA2836480A1 (en) 2012-11-29
SG195049A1 (en) 2013-12-30
CO6811862A2 (es) 2013-12-16
US20140163100A1 (en) 2014-06-12
EA201391578A1 (ru) 2014-05-30
CL2013003358A1 (es) 2014-08-01

Similar Documents

Publication Publication Date Title
PH12013502443A1 (en) Methods of treating multiple sclerosis and preserving and/or increasing myelin content
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
IN2014DN09782A (enExample)
PH12014501639A1 (en) Pharmaceutical compositions and methods
MX2013003076A (es) Terapeuticos contra cancer de mama.
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
CO6731092A2 (es) Nueva forma de administración de inhibidor de encefalinasa
MX356025B (es) Uso de glicopirrolato para tratar taquicardia.
GB201316955D0 (en) Composition comprising a diindolymethane and a retinoid to treat a skin condition
MX357510B (es) Metodos para tratar ataques de gota.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX2014000567A (es) Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
AR080933A1 (es) Tratamiento de esclerosis multiple con masitinib
MX337139B (es) Composicion de miel con l-alanil-l-glutamina.
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
AR084169A1 (es) Combinacion que comprende un derivado de la familia de las combretastatinas y cetuximab
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
TN2013000247A1 (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
Trainor Broome Taxi rides
IN2014KN01142A (enExample)
NI201300052A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
UA98076C2 (ru) Применение немодифицированных фуллеренов с60 в качестве противоопухолевых агентов в терапии злокачественных новообразований